AptaBio Therapeutics Inc
KOSDAQ:293780
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
A
|
AptaBio Therapeutics Inc
KOSDAQ:293780
|
211B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
72.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
AptaBio Therapeutics Inc
Glance View
Aptabio Therapeutics, Inc. operates as a pharmaceutical biotechnology company that develops intractable innovative drugs based on original platform technology. The company is headquartered in Yongin, Gyeonggi-Do and currently employs 28 full-time employees. The company went IPO on 2019-06-12. The firm is developing anti-cancer drugs, drugs for inflammatory and fibrotic diseases and diabetic complications drugs, among others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for AptaBio Therapeutics Inc is 33%, which is above its 3-year median of 15.3%.
Over the last 2 years, AptaBio Therapeutics Inc’s Gross Margin has increased from 24.2% to 33%. During this period, it reached a low of 7.6% on Mar 31, 2025 and a high of 33% on Oct 30, 2025.